Targeted inhibition of PDGFRA with avapritinib, markedly enhances lenvatinib efficacy in hepatocellular carcinoma in vitro and in vivo: clinical implications

Targeted inhibition of PDGFRA with avapritinib, markedly enhances lenvatinib efficacy in hepatocellular carcinoma in vitro and in vivo: clinical implications

Abstract Background Lenvatinib, a tyrosine kinase receptor inhibitor, has emerged as a frontline therapeutic strategy for the management of advanced hepatocellular carcinoma (HCC). However, the modest response rate observed with lenvatinib and the rapid emergence of chemoresistance highlight the urg...

Full description

Saved in:
Bibliographic Details
Main Authors: Bixing Zhao, Yang Zhou, Niangmei Cheng, Xiaoyuan Zheng, Geng Chen, Xin Qi, Xiangzhi Zhang, Fei Wang, Qiuyu Zhuang, Yehuda G. Assaraf, Xiaolong Liu, Yingchao Wang, Yongyi Zeng
Format: Article
Language:English
Published: BMC 2025-05-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Hepatocellular carcinoma
Lenvatinib
Resistance
PDGFRA
Avapritinib
Online Access:https://doi.org/10.1186/s13046-025-03386-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13046-025-03386-8

Similar Items